Indeed, in mouse models, RIPK1 inhibitors have been shown to prevent or alleviate clinical symptoms of various diseases, including SIRS, ischemia-induced tissue injury, neurodegeneration, and bacterial and viral infections [2]. This evidence concerns the gene RIPK1 and viral infectious disease.